Navigation Links
Karolinska Development and Uminova Invest Sign Co-operation Agreement

STOCKHOLM and UMEA, Sweden, January 14 /PRNewswire/ -- Karolinska Development AB and Uminova Invest AB have entered into a co-operation agreement that will enrich the flow of investment opportunities available to Karolinska Development and enable cost effective commercial development for Uminova Invest's portfolio companies. The agreement involves evaluation of potential investments; advise to existing portfolio companies as well as exit issues.

Uminova Invest is a regional private equity capital firm providing capital and competence to prospective growth companies and entrepreneurs with a connection to the Umea University or other educational and research activities in the county of Vasterbotten.

"Umea region excels having created a very strong cluster of life science innovations over the past years and this agreement offers us access to some very exciting commercial opportunities", says Conny Bogentoft, CEO of Karolinska Development.

"Over the past years we have had an ongoing exchange with Karolinska Development, this has now been formalized. This formal co-operation agreement provides further opportunities to create viable companies", says Jan Olsson, CEO of Uminova Invest.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first in class products.

About Uminova Invest

Uminova Invest focuses on prospective growth companies and people with interesting ideas and an entrepreneur spirit at a stage when the addition of capital and competence is vital for the company's growth. The idea, product or service must be unique with a high market potential, and must have a connection to the Umea University or other educational and research activities in the county of Vasterbotten.

    For more information, please contact:

    Conny Bogentoft CEO Karolinska Development
    Tel: +46(0)706-88-61-43, e-mail:

    Jan Olsson CEO Uminova Invest
    Tel: +46(0)703-44-16-80, email:

SOURCE Karolinska Development AB and Uminova Invest AB

SOURCE Karolinska Development AB and Uminova Invest AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
2. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
3. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
4. Karolinska Development Closes Fully Subscribed New Share Issue
5. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
Post Your Comments:
(Date:10/12/2017)... NY (PRWEB) , ... October 12, 2017 , ... ... of Sciences today announced the three Winners and six Finalists of the 2017 ... given annually by the Blavatnik Family Foundation and administered by the New York ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):